Reversal of voltage-dependent erectile responses in the zucker obese-diabetic rat by rosuvastatin-altered rhoa/rho-kinase signaling

Journal of Sexual Medicine

Volumn 6, Issue SUPPL. 3, 2009, Pages 269-278

  Wingard, Christopher J ^a   Moukdar, Fatiha ^a   Prasad, Raju Y ^a   Cathey, Brook L ^a   Wilkinson, Lois ^a  

^a EAST CAROLINA UNIVERSITY   (United States)

Author keywords

Metabolic syndrome x; Nitric oxide synthase; Rosuvastatin

Indexed keywords

H 1152; MESSENGER RNA; RHO KINASE; RHO KINASE INHIBITOR; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; ROSUVASTATIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CONFERENCE PAPER; CONTROLLED STUDY; CORPUS CAVERNOSUM; DIABETES MELLITUS; ERECTILE DYSFUNCTION; HYPERTENSION; LEAN BODY WEIGHT; MALE; MEAN ARTERIAL PRESSURE; METABOLIC SYNDROME X; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY ANALYSIS; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; WESTERN BLOTTING; ZUCKER DIABETIC FATTY RAT;

EID: 61849104506     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/j.1743-6109.2008.01184.x     Document Type: Conference Paper

References (61)

1. Mokdad AH, Ford ES, Bowman BA, Nelson DE, Engelgau MM, Vinicor F, Marks JS. Diabetes trends in the U.S.: 1990-1998. Diabetes Care 2000; 23: 1278-83.
2. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-607.
3. Reilly MP, Rader DJ. The metabolic syndrome: More than the sum of its parts? Circulation 2003; 108: 1546-51.
4. Heaton JP, Adams MA. Causes of erectile dysfunction. Endocrine 2004; 23: 119-23.
5. Seftel AD, Sun P, Swindle R. The prevalence of hypertension, hyperlipidemia, diabetes mellitus and depression in men with erectile dysfunction. J Urol 2004; 171: 2341-5.
6. Shabbir M, Mikhailidis DM, Morgan RJ. Erectile dysfunction: An underdiagnosed condition associated with multiple risk factors. Curr Med Res Opin 2004; 20: 603-6.
7. Yeh HC, Wang CJ, Lee YC, Hsiao HL, Wu WJ, Chou YH, Huang CH. Association among metabolic syndrome, testosterone level and severity of erectile dysfunction. Kaohsiung J Med Sci 2008; 24: 240-7.
8. Corona G, Mannucci E, Petrone L, Schulman C, Balercia G, Fisher AD, Chiarini V, Forti G, Maggi M. A comparison of NCEP-ATPIII and IDF metabolic syndrome definitions with relation to metabolic syndrome-associated sexual dysfunction. J Sex Med 2007; 4: 789-96.
9. Corona G, Mannucci E, Petrone L, Balercia G, Paggi F, Fisher AD, Lotti F, Chiarini V, Fedele D, Forti G, Maggi M. NCEP-ATPIII-defined metabolic syndrome, type 2 diabetes mellitus, and prevalence of hypogonadism in male patients with sexual dysfunction. J Sex Med 2007; 4: 1038-45.
10. Burnett AL. Metabolic syndrome, endothelial dysfunction, and erectile dysfunction: Association and management. Curr Urol Rep 2005; 6: 470-5.
11. Matfin G, Jawa A, Fonseca VA. Erectile dysfunction: Interrelationship with the metabolic syndrome. Curr Diab Rep 2005; 5: 64-9.
12. Fonseca V, Jawa A. Endothelial and erectile dysfunction, diabetes mellitus, and the metabolic syndrome: Common pathways and treatments? Am J Cardiol 2005; 96: 13M-18M.
13. Shabsigh R, Arver S, Channer KS, Eardley I, Fabbri A, Gooren L, Heufelder A, Jones H, Meryn S, Zitzmann M. The triad of erectile dysfunction, hypogonadism and the metabolic syndrome. Int J Clin Pract 2008; 62: 791-8.
14. Billups KL, Bank AJ, Padma-Nathan H, Katz SD, Williams RA. Erectile dysfunction as a harbinger for increased cardiometabolic risk. Int J Impot Res 2008; 20: 236-42.
15. Miner M, Billups KL. Erectile dysfunction and dyslipidemia: Relevance and role of phosphodiesterase type-5 inhibitors and statins. J Sex Med 2008; 5: 1066-78.
16. Kupelian V, Shabsigh R, Araujo AB, O'Donnell AB, McKinlay JB. Erectile dysfunction as a predictor of the metabolic syndrome in aging men: Results from the Massachusetts male aging study. J Urol 2006; 176: 222-6.
17. Demir T, Demir O, Kefi A, Comlekci A, Yesil S, Esen A. Prevalence of erectile dysfunction in patients with metabolic syndrome. Int J Urol 2006; 13: 385-8.
18. Shabsigh R, Shah M, Sand M. Erectile dysfunction and men's health: Developing a comorbidity risk calculator. J Sex Med 2008; 5: 1237-43.
19. Haffner SM. Statin therapy for the treatment of diabetic dyslipidemia. Diabetes Metab Res Rev 2003; 19: 280-7.
20. Maron DJ, Fazio S, Linton MF. Current perspectives on statins. Circulation 2000; 101: 207-13.
21. Endres M, Laufs U. Effects of statins on endothelium and signaling mechanisms. Stroke 2004; 35 (11 suppl): 2708-11.
22. Sessa WC. Can modulation of endothelial nitric oxide synthase explain the vasculoprotective actions of statins? Trends Mol Med 2001; 7: 189-91.
23. Wolfrum S, Jensen KS, Liao JK. Endothelium-dependent effects of statins. Arterioscler Thromb Vasc Biol 2003; 23: 729-36.
24. Kato T, Hashikabe H, Iwata C, Akimoto K, Hattori Y. Statin blocks Rho/ Rho-kinase signalling and disrupts the actin cytoskeleton: Relationship to enhancement of LPS-mediated nitric oxide synthesis in vascular smooth muscle cells. Biochim Biophys Acta 2004; 1689: 267-72.
25. Laufs U, Endres M, Custodis F, Gertz K, Nickenig G, Liao JK, Bohm M. Suppression of endothelial nitric oxide production after withdrawal of statin treatment is mediated by negative feedback regulation of rho GTPase gene transcription. Circulation 2000; 102: 3104-10.
26. Wingard CJ, Johnson JA, Holmes A, Prikosh A. Improved erectile function following Rho-kinase inhibition in a rat castrate model of erectile dysfunction. Am J Physiol Regul Integr Comp Physiol 2003; 284: R1572-9.
27. Wingard C, Fulton D, Husain S. Altered penile vascular reactivity and erection in the Zucker obese-diabetic rat. J Sex Med 2007; 4: 348-62.
28. Husain S, Young D, Wingard CJ. Role of PKCalpha and PKC iota in phenylephrine-induced contraction of rat corpora cavernosa. Int J Impot Res 2004; 16: 325-33.
29. Mills TM, Chitaley K, Wingard CJ, Lewis RW, Webb RC. Effect of Rho-kinase inhibition on vasoconstriction in the penile circulation. J Appl Physiol 2001; 91: 1269-73.
30. Mills TM, Lewis RW, Wingard CJ, Linder AE, Jin L, Webb RC. Vasoconstriction RhoA/Rho-kinase and the erectile response. Int J Impot Res 2003; 15 (5 suppl): S20-4.
31. Saenzd TI, Angulo J, Cellek S, Gonzalez-Cadavid N, Heaton J, Pickard R, Simonsen U. Pathophysiology of erectile dysfunction. J Sex Med 2005; 2: 26-39.
32. Somlyo AP, Somlyo AV. Ca2+ sensitivity of smooth muscle and nonmuscle myosin II. Modulated by G proteins, kinases, and myosin phosphatase. Physiol Rev 2003; 83: 1325-58.
33. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001; 414: 813-20.
34. Chardin PGT. Pase regulation: Getting aRnd rock and rho inhibition. Curr Biol 2003; 13: R702-4.
35. Frisbee JC. Remodeling of the skeletal muscle microcirculation increases resistance to perfusion in obese Zucker rats. Am J Physiol Heart Circ Physiol 2003; 285: H104-11.
36. Frisbee JC. Enhanced arteriolar alpha-adrenergic constriction impairs dilator responses and skeletal muscle perfusion in obese Zucker rats. J Appl Physiol 2004; 97: 764-72.
37. Oltman CL, Davidson EP, Coppey LJ, Kleinschmidt TL, Lund DD, Yorek MA. Attenuation of vascular/neural dysfunction in Zucker rats treated with enalapril or rosuvastatin. Obesity (Silver Spring) 2008; 16: 82-9.
38. Vignozzi L, Morelli A, Filippi S, Ambrosini S, Mancina R, Luconi M, Mungai S, Vannelli GB, Zhang XH, Forti G, Maggi M. Testosterone regulates RhoA/Rho-kinase signaling in two distinct animal models of chemical diabetes. J Sex Med 2007; 4: 620-30.
39. Luttrell IP, Swee M, Starcher B, Parks WC, Chitaley K. Erectile dysfunction in the type II diabetic db/db mouse: Impaired venoocclusion with altered cavernosal vasoreactivity and matrix. Am J Physiol Heart Circ Physiol 2008; 294: H2204-11.
40. Jin L, Burnett AL. RhoA/Rho-kinase in erectile tissue: Mechanisms of disease and therapeutic insights. Clin Sci (Lond) 2006; 110: 153-65.
41. Christ G, Wingard C. Calcium sensitization as a pharmacological target in vascular smooth-muscle regulation. Curr Opin Investig Drugs 2005; 6: 920-33.
42. Gonzalez-Cadavid NF, Rajfer J. Therapy of erectile dysfunction: Potential future treatments. Endocrine 2004; 23: 167-76.
43. Mason JC. Statins and their role in vascular protection. Clin Sci (Lond) 2003; 105: 251-66.
44. Mason RP. Molecular basis of differences among statins and a comparison with antioxidant vitamins. Am J Cardiol 2006; 98: 4P-41P.
45. Mason RP, Walter MF, Day CA, Jacob RF. Intermolecular differences of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors contribute to distinct pharmacologic and pleiotropic actions. Am J Cardiol 2005; 96: 11F-23F.
46. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature 1990; 343: 425-30.
47. Casey PJ. Protein lipidation in cell signaling. Science 1995; 268: 221-5.
48. Fibbi B, Morelli A, Marini M, Zhang XH, Mancina R, Vignozzi L, Filippi S, Chavalmane A, Silvestrini E, Colli E, Adorini L, Vannelli GB, Maggi M. Atorvastatin but not elocalcitol increases sildenafil responsiveness in spontaneously hypertensive rats by regulating the RhoA/ROCK pathway. J Androl 2008; 29: 70-84.
49. Burnett AL. Role of nitric oxide in the physiology of erection. Biol Reprod 1995; 52: 485-9.
50. Burnett AL. Novel nitric oxide signaling mechanisms regulate the erectile response. Int J Impot Res 2004; 16 (1 suppl): S15-9.
51. Rikitake Y, Liao JK. ROCKs as therapeutic targets in cardiovascular diseases. Expert Rev Cardiovasc Ther 2005; 3: 441-51.
52. Nangle MR, Cotter MA, Cameron NE. Effects of rosuvastatin on nitric oxide-dependent function in aorta and corpus cavernosum of diabetic mice: Relationship to cholesterol biosynthesis pathway inhibition and lipid lowering. Diabetes 2003; 52: 2396-402.
53. Jones SP, Gibson MF, Rimmer DM, III, Gibson TM, Sharp BR, Lefer DJ. Direct vascular and cardioprotective effects of rosuvastatin, a new HMG-CoA reductase inhibitor. J Am Coll Cardiol 2002; 40: 1172-8.
54. Endres M, Laufs U, Huang Z, Nakamura T, Huang P, Moskowitz MA, Liao JK. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci USA 1998; 95: 8880-5.
55. Trebicka J, Hennenberg M, Laleman W, Shelest N, Biecker E, Schepke M, Nevens F, Sauerbruch T, Heller J. Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA/Rho-kinase and activation of endothelial nitric oxide synthase. Hepatology 2007; 46: 242-53.
56. Erdos B, Snipes JA, Tulbert CD, Katakam P, Miller AW, Busija DW. Rosuvastatin improves cerebrovascular function in Zucker obese rats by inhibiting NAD(P)H oxidase-dependent superoxide production. Am J Physiol Heart Circ Physiol 2006; 290: H1264-70.
57. Shinozaki K, Nishio Y, Ayajiki K, Yoshida Y, Masada M, Kashiwagi A, Okamura T. Pitavastatin restores vascular dysfunction in insulin-resistant state by inhibiting NAD(P)H oxidase activity and uncoupled endothelial nitric oxide synthase-dependent superoxide production. J Cardiovasc Pharmacol 2007; 49: 122-30.
58. Wenzel P, Daiber A, Oelze M, Brandt M, Closs E, Xu J, Thum T, Bauersachs J, Ertl G, Zou MH, Forstermann U, Munzel T. Mechanisms underlying recoupling of eNOS by HMG-CoA reductase inhibition in a rat model of streptozotocin-induced diabetes mellitus. Atherosclerosis 2008; 198: 65-76.
59. Chen W, Pendyala S, Natarajan V, Garcia JG, Jacobson JR. Endothelial cell barrier protection by simvastatin: GTPase regulation and NADPH oxidase inhibition. Am J Physiol Lung Cell Mol Physiol 2008; 295: L575-83.
60. Sicard P, Acar N, Gregoire S, Lauzier B, Bron AM, Creuzot-Garcher C, Bretillon L, Vergely C, Rochette L. Influence of rosuvastatin on the NAD(P)H oxidase activity in the retina and electroretinographic response of spontaneously hypertensive rats. Br J Pharmacol 2007; 151: 979-86.
61. Chitaley K, Wingard CJ, Clinton W, Branam H, Stopper VS, Lewis RW, Mills TM. Antagonism of Rho-kinase stimulates rat penile erection via a nitric oxide-independent pathway. Nat Med 2001; 7: 119-22.